Clicky

Genetic Technologies Limited(GTG)

Description: Genetic Technologies Limited is a molecular diagnostics company. The Company is engaged in the provision of molecular risk assessment for cancer. The Company offers predictive testing and assessment tools for physicians to manage women's health. The Company's lead product, BREVAGenplus, is a clinically validated risk assessment test for non-hereditary breast cancer. The Company markets BREVAGenplus to healthcare professionals in breast healthcare and imaging centers, as well as to obstetricians/gynecologists (OBGYNs) and breast cancer risk assessment specialists, such as breast surgeons. The Company operates in Australia, the United States and Switzerland. The Company's subsidiaries include Genetic Technologies Corporation Pty. Ltd. and Phenogen Sciences Inc. Genetic Technologies Corporation Pty. Ltd. is engaged in genetic testing. The Company has launched the BREVAGen test across the United States through Phenogen Sciences Inc.


Keywords: Medicine Biotechnology Cancer Clinical Medicine Imaging Breast Cancer Molecular Diagnostics Medical Genetics Genetic Testing Predictive Medicine Assessment Tools Myriad Genetics Non Hereditary Breast Cancer

Home Page: genetype.com

GTG Technical Analysis

60-66 Hanover Street
Fitzroy, VIC 3065
Australia
Phone: 61 3 8412 7000


Officers

Name Title
Mr. Simon Morriss Chief Exec. Officer
Dr. Richard Allman Ph.D. Chief Scientific Officer
Mr. Carl S. Stubbings BSc Chief Commercial Officer
Mr. Tony Di Pietro AGIA, B.Com, C.A., CPA, M.A.I.C.D. CFO & Company Sec.
Mr. Paul Keith Mathieson Viney B. Bus, FCI, FCPA, FGIA Consultant
Mr. Kevin Camilleri Chief Exec. Officer of EasyDNA

Exchange: AU

Country: AU

Currency: Australian Dollar (A$)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 1.6859
Price-to-Sales TTM: 2.0034
IPO Date:
Fiscal Year End: June
Full Time Employees: 52
Back to stocks